Ascorbate-2-phosphate in red cell preservation. Clinical trials and active components

Publisher Website
Google Scholar
Abstract
A red cell additive solution (AS‐005) containing ascorbate‐2‐phosphate (AsP) to maintain 2,3‐diphosphoglycerate, plus adenine, phosphate, and mannitol to retain viability and reduce hemolysis, was evaluated by human clinical trials. A crossover design was used with another additive solution (Nutricel AS‐3, Cutter Laboratories) serving as the control for each donor. Each additive solution was evaluated at 35 and 42 days of storage. There was no significant difference between the red cell viability of the two storage solutions at either time period. Split‐bag, AS‐005 in vitro studies at two temperatures (2.5 and 5.5° C), both within the range of 1 to 6° C approved by the American Association of Blood Banks and the Food and Drug Administration, resulted in dramatically different in vitro parameters, including a threefold difference in 2,3‐diphosphoglycerate (2,3‐DPG), a fivefold difference in glucose, and significant differences in pH and adenosine triphosphate. High‐pressure liquid chromatography data confirmed the preliminary report that 1 to 2 percent (wt/wt) oxalate was present in preparations of AsP. In vitro storage data confirmed that oxalate is the active component of AsP that preserves 2,3‐DPG during storage.

This publication has 1 reference indexed in Scilit: